Cell Proliferation, Cell Cycle Abnormalities, and Cancer Outcome in Patients with Barrett's Esophagus: A Long-term Prospective Study

Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma

Cell Cycle Phase Abnormalities Do Not Account for Disordered Proliferation in Barrett's Carcinogenesis

To review the current knowledge on the genetic alterations involved in the development and progression of Barrett's esophagus-associated neoplastic lesions. Barrett's esophagus (BE) is a premalignant condition in which the normal squamous epithelium of the esophagus is replaced by metaplastic columnar epithelium. BE predisposes patients to the development of esophageal adenocarcinoma. Endoscopic surveillance can detect esophageal adenocarcinomas when they are early and curable, but most of the adenocarcinomas are detected at an advanced stage. Despite advances in multimodal therapy, the prognosis for invasive esophageal adenocarcinoma is poor. A better understanding of the molecular evolution of the Barrett's metaplasia to dysplasia to adenocarcinoma sequence may allow improved diagnosis, therapy, and prognosis. The authors reviewed data from the published literature to address what is known about the molecular changes thought to be important in the pathogenesis of BE-associated neoplastic lesions. The progression of Barrett's metaplasia to adenocarcinoma is associated with several changes in gene structure, gene expression, and protein structure. Some of the molecular alterations already showed promise as markers for early cancer detection or prognostication. Among these, alterations in the p53 and p16 genes and cell cycle abnormalities or aneuploidy appear to be the most important and well-characterized molecular changes. However, the exact sequence of events is not known, and probably multiple molecular pathways interact and are involved in the progression of BE to adenocarcinoma. Further research into the molecular biology of BE-associated adenocarcinoma will enhance our understanding of the genetic events critical for the initiation and progression of Barrett's adenocarcinoma, leading to more effective surveillance and treatment.

Several indirect evidences are available to indicate that abnormalities in cell cycle may contribute to pathogenesis of Huntington's disease (HD). Here, we show that the cell cycle progression in STsdh(Q111)/Hdh(Q111)cells, a cell model of HD, is delayed in S and G2-M phases compared to control STHdhQ7/HdhQ7cells. Expression of 17 genes, like PCNA and CHEK1, was increased in STHdh(Q111)/Hdh(Q111)cells. Increased expressions of PCNA, CHEK1 and CCNA2, and an enhanced phosphorylation of Rb1 were observed in primary cortical neurons expressing mutant N-terminal huntingtin (HTT), R6/2 mice and STHdh(Q111)/Hdh(Q111) cells. This increase in the expressions of PCNA, CHEK1 and CCNA2 was found to be the result of decreased expressions of miR-432, miR-146a, and (miR-19a and miR-146a), respectively. Enhanced apoptosis was observed at late S phase and G2-M phase in STHdh(Q111)/Hdh(Q111)cells. Exogenous expressions of these miRNAs in STHdh(Q111)/Hdh(Q111) cells rescued the abnormalities in cell cycle and apoptosis. We also observed that inhibitors of cell cycle could decrease cell death in a cell model of HD. Based on these results obtained in cell and animal model of HD, we propose that inhibition of cell cycle either by miRNA expressions or by using inhibitors could be a potential approach for the treatment of HD.

Cell cycle abnormalities in Barrett's esophagus: Further insights

In our prospective study, flow cytometric analysis of cellular DNA and RNA content was performed on unfixed fresh specimens of colorectal adenocarcinoma taken from 176 patients. Of the 176 tumors, 113 (64%) were aneuploid. There was no correlation between aneuploidy and tumor stage, grade, location, or size. After a median follow-up of 5.6 years, no correlation between DNA or RNA content and patient survival was found. DNA content alone was not an independent prognostic factor when the colorectal carcinomas were segregated by curable and incurable stages. However, normal mucosa, diploid tumors, and aneuploid tumors showed progressively higher proliferation and higher RNA and DNA indices. Proliferative fraction--defined as the percentage of cells in S + G2 and M phases of the cell cycle--was significantly related to ploidy and to Dukes' stage. Despite these correlations, we did not detect a significant influence of proliferative fraction on survival when patients were segregated above or below the mean proliferative fraction for all tumors. More accurate methods of identifying the proliferative fraction of tumor cells are currently being pursued. While the role of flow cytometry in the evaluation and management of patients with colorectal carcinoma is still undefined for a number of other cellular parameters, it seems unlikely that DNA index, RNA index, or the proliferative fractions calculated from the DNA histogram, will, of themselves, represent independent prognostic factors.

c-Jun is a component of the transcription factor AP-1, which is activated by a wide variety of extracellular stimuli. The regulation of c-Jun is complex and involves both increases in the levels of c-Jun protein as well as phosphorylation of specific serines (63 and 73) by Jun N-terminal kinase (JNK). We have used fibroblasts derived from c-Jun null embryos to define the role of c-Jun in two separate processes: cell growth and apoptosis. We show that in fibroblasts, c-Jun is required for progression through the G1 phase of the cell cycle; c-Jun-mediated G1 progression occurs by a mechanism that involves direct transcriptional control of the cyclin D1 gene, establishing a molecular link between growth factor signaling and cell cycle regulators. In addition, c-Jun protects cells from UV-induced cell death and cooperates with NF-kappaB to prevent apoptosis induced by tumor necrosis factor alpha (TNFalpha). c-Jun mediated G1 progression is independent of phosphorylation of serines 63/73; however, protection from apoptosis in response to UV, a potent inducer of JNK/SAP kinase activity, requires serines 63/73. The results reveal critical roles for c-Jun in two different cellular processes and show that different extracellular stimuli can target c-Jun by distinct biochemical mechanisms.

Polycystic Kidneys Diseases (PKDs) represent a group of disorders characterized by the growth of fluid filled cysts in kidneys and other organs. No effective treatment is currently available for PKDs. A link between dysfunctional cilia and cell cycle regulation has been recently discovered as the most proximal trigger of cystogenesis. We examined the benefit of therapeutic correction of the cell cycle dysregulation in PKD with the cyclin dependent kinase (CDK) inhibitor roscovitine. Our data show that CDK inhibition results in the robust, long lasting arrest of cystogenesis in both slowly progressive and in aggressive mouse models of PKD. Dissection of the molecular mechanism of CDK inhibitor action shows effective cell cycle arrest, transcriptional inhibition and attenuation of apoptosis. Roscovitine treatment has proven highly effective in preserving the renal function in treated animals. We also detected significant downregulation of cAMP and aquaporin 2 in treated kidneys, suggesting the effect of CDK inhibition on preservation of epithelial differentiation. CDK inhibition was shown to be efficacious in multiple other types of renal diseases with abnormal cell cycle and proliferation. Thus, therapies directly targeting coordinate regulation of proliferation and apoptosis are emerging as effective approaches to treat multiple renal diseases.

Esophageal adenocarcinoma (EAC) is a deadly cancer with high mortality rate, especially in economically advanced countries, while Barrett's esophagus (BE) is reported to be a precursor that strongly increases the risk of EAC. Due to the complexity of these diseases, their molecular mechanisms have not been revealed clearly. This study aims to explore the gene signatures shared between BE and EAC based on integrated network analysis. We obtained EAC- and BE-associated microarray datasets GSE26886, GSE1420, GSE37200, and GSE37203 from the Gene Expression Omnibus and ArrayExpress using systematic meta-analysis. These data were accompanied by clinical data and RNAseq data from The Cancer Genome Atlas (TCGA). Weighted gene co-expression network analysis (WGCNA) and differentially expressed gene (DEG) analysis were conducted to explore the relationship between gene sets and clinical traits as well as to discover the key relationships behind the co-expression modules. A differentially expressed gene-based protein–protein interaction (PPI) complex was used to extract hub genes through Cytoscape plugins. As a result, 403 DEGs were excavated, comprising 236 upregulated and 167 downregulated genes, which are involved in the cell cycle and replication pathways. Forty key genes were identified using modules of MCODE, CytoHubba, and CytoNCA with different algorithms. A dark-gray module with 207 genes was identified which having a high correlation with phenotype (gender) in the WGCNA. Furthermore, five shared hub gene signatures (SHGS), namely, pre-mRNA processing factor 4 (PRPF4), serine and arginine-rich splicing factor 1 (SRSF1), heterogeneous nuclear ribonucleoprotein M (HNRNPM), DExH-Box Helicase 9 (DHX9), and origin recognition complex subunit 2 (ORC2), were identified between BE and EAC. SHGS enrichment denotes that RNA metabolism and splicosomes play a key role in esophageal cancer development and progress. We conclude that the PPI complex and WGCNA co-expression network highlight the importance of phenotypic identifying hub gene signatures for BE and EAC.

The incidence of adenocarcinoma of the distal esophagus is rapidly increasing in the Western world. The histopathological sequence of (Barrett's) metaplasia, which develops as a consequence of chronic reflux, to dysplasia and then to carcinoma is well established for these tumors. In Barrett's esophagus a variety of molecular changes have been characterized and correlated with tumor initiation and progression. Among the early changes in premalignant stages of metaplasia are alterations of the transcripts of FHIT, a presumptive tumor suppressor gene which spans the common fragile site FRA3B. Mutations of p53 seem to accumulate mainly in the transition from low to high grade dysplasia. Inactivation of other tumor suppressor genes by mutation (APC, p16) or hypermethylation (p16) as well as amplification of oncogenes such as cerbB2 are relatively late events in the development of adenocarcinoma. Among the phenotypic changes in Barrett's esophagus are an expansion of the Ki67 proliferation compartment which correlates with the degree of dysplasia. Moreover, accumulation of rab11 molecules which are involved in membrane trafficking has been reported to be specific for the loss of polarity seen in low grade dysplasia. Reduced expression of the cadherin/catenin complex as well as increased expression of various proteases develop chiefly in invasive carcinomas. Despite the progress that has been made in the identification of molecular markers in Barrett's carcinoma, to date the histopathological diagnosis of high grade dysplasia in endoscopic biopsies remains the best predictor of invasive cancer. Immunohistochemistry applying a panel of antibodies including p53, Mib-1 or rab11 can be helpful to diagnose regenerative metaplastic epithelium or low and high grade dysplasia.

Cell cycle dysregulation is a prerequisite for cancer formation. However, whether the type of cell cycle dysregulation event a cell incurs during transformation to malignancy influences the type of cancer that evolves or clinical outcome is unknown. In a comprehensive analysis of cell cycle dysregulation in breast cancer patient tumors, we associate mutations in each of four cell cycle checkpoint kinase genes, ATM, CHEK2, ATR and CHEK1, with known tumor characteristics and clinical outcome, and test these associations experimentally using transgenic mice, patient-derived xenografts and breast cancer cell line model systems. Results of this work demonstrate that dysregulation of specific cell cycle checkpoint kinases differently impacts the type of breast cancer that evolves in patients and in experimental model systems, and influences treatment responsiveness and disease progression. For instance, CHEK2 mutations associate preferentially with the incidence of metastatic, premenopausal estrogen receptor (ER)+/HER2- breast cancer in patient data (p=0.001) that is resistant to standard frontline therapy (HR=6.15, p=0.01). These associations appear causal when tested in an immune-competent genetically-engineered mouse model of Chk2 loss, in patient-derived xenograft, and in cell line experiments. On the other hand, ATR mutation by itself is not frequent in ER+/HER2- breast cancer, but co-incident mutation of ATR and TP53 is 2-fold enriched (p=0.002) and associates with metastatic progression (HR=2.01, p=0.007). Concordantly, ATR dysregulation induces metastatic phenotypes in ER+/HER- TP53 mutant, but not in TP53 wildtype, cell lines. Together, these results systematize the impact of individual cell cycle checkpoint kinases on the evolution of cancer subtypes, and on disease progression. Statement of Significance These findings reframe the paradigm of breast cancer classification through the lens of early cell cycle dysregulation events by demonstrating that cell cycle decisions during malignant transformation can direct the type of breast cancer that evolves, how it will respond to treatment, and whether it will metastasize. This work provides rationale for streamlined testing of checkpoint kinase dysregulation to improve precision diagnostics for cancer patients. Citation Format: Sinem Seker, Elena Oropeza, Sabrina Carrel, Aloran Mazumder, Nindo Punturi, Jonathan Lei, Meenakshi Anurag, Bora Lim, Matthew Bainbridge, Svasti Haricharan. Cell cycle dysregulation in breast cancer: why the details matter [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-10-02.

New xanthones and cytotoxic constituents from Garcinia mangostana fruit hulls against human hepatocellular, breast, and colorectal cancer cell lines

This protocol describes a method to permit the tracking of cells through the cell cycle without requiring the cells to be synchronized. Achieving cell synchronization can be difficult for many cell systems. Standard practice is to block cell cycle progression at a specific stage and then release the accumulated cells producing a wave of cells progressing through the cycle in unison. However, some cell types find this block toxic resulting in abnormal cell cycling, or even mass death. Bromodeoxyuridine (BrdU) uptake can be used to track the cell cycle stage of individual cells. Cells incorporate this synthetic thymidine analog, while synthesizing new DNA during S phase. By providing BrdU for a brief period it is possible to mark a pool of cells that were in S phase while the BrdU was present. These cells can then be tracked through the remainder of the cell cycle and into the next round of replication, permitting the duration of the cell cycle phases to be determined without the need to induce a potentially toxic cell cycle block. It is also possible to determine and correlate the expression of both internal and external proteins during subsequent stages of the cell cycle. These can be used to further refine the assignment of cell cycle stage or assess effects on other cellular functions such as checkpoint activation or cell death.

This month's issue of the Archives of Pathology & Laboratory Medicine includes a unique special section on "Molecular Signatures of Lung and Pleural Tumors" that represents the proceedings of a special Joint Symposium of the European Working Groups for Molecular Pathology and Pulmonary Pathology at the 21st European Congress of Pathology in Istanbul, Turkey, in September 2007. This symposium and the subsequent special section were organized by Dr Helmut Popper of the Institute of Pathology at the Medical University of Graz, Graz, Austria, president elect of the Austrian Society of Pathologists and immediate past president of the European Working Group for Pulmonary Pathology. In this brief review, we have provided some definitions of terms and concepts used in the proceedings of the "Molecular Signatures of Lung and Pleural Tumors" special section for those readers who are not already familiar with molecular pathology.Molecular pathology may have once been a specialized component of the research laboratory or the clinical laboratory, but today molecular diagnostic and prognostic techniques are in common use within the anatomic pathology laboratory, especially in the realm of infectious organism diagnosis and cancer diagnosis. Molecular testing continues to expand as more easily obtainable archival paraffin-embedded tissue replaces fresh and frozen tissues as the source of DNA and RNA needed for molecular analysis, and as newer technologies allow for more streamlined methods of testing. This review addresses the increased application of molecular testing in lung pathology, specifically how the current state of molecular pathology may be applied to practical, everyday lung pathology diagnosis.Genes, made up of nucleic acids, contain the information necessary for the construction of proteins from amino acids within a cell. Genes code for proteins required for metabolic reactions and cellular structure. DNA makes up genes, and RNA transcribes the genetic code held within the DNA into proteins. The genetic code within the genes is composed of nucleic acids, for which nucleotides are the building blocks. Nucleotides, made up of a sugar-phosphate backbone with a nitrogenous base, are either purines—adenine (A) and guanine (G) in DNA and RNA— or pyrimidines—thymine (T) and cytosine (C) in DNA (uracil [U] replaces T in RNA). The nucleotides that make up the genes are arranged in a double-stranded right-handed helix. Nucleotides in DNA are arranged sequentially so that a gene will code for a matching protein. Within a double helix pattern, A, a purine, always binds with T, a pyrimidine, and G always binds with C, giving a nucleotide sequence for which 1 strand is a "mirror image" of the other strand.1–6There are 46 chromosomes (23 pairs) in a human diploid cell, on which all genes are located. Chromosomes are paired, and as such a gene is found on a locus on each of the 2 paired chromosomes, giving 2 copies, or alleles, of genes. Gametes are haploid rather than diploid and therefore contain only 1 allele for each gene. Diploid status is reestablished when the nuclear material from an egg and sperm combine during fertilization.1–6Transcription, the synthesis of messenger RNA (mRNA) from a DNA strand, is a key step in the formation of protein coded by DNA. During transcription, enzymes called topoisomerases break a DNA strand and allow the DNA double-helix to uncoil, giving 2 DNA strands, 1 of which is the template for mRNA, called the DNA template. Base pairs are matched with the DNA template to produce a mirror image of the DNA template, except with the substitution of U for T, forming a strand of mRNA. A series of 3 base pairs in a gene, called a codon, code for a specific amino acid, so that a series of codons code for a particular sequence of amino acids resulting in the synthesis of a specific protein. Translation, the assembly of the protein molecule from the mRNA template, occurs with the addition of amino acids in a particular sequence based on the specificity of the mRNA. Transfer RNA assists in translation.1–6After translation, modifications to the newly formed protein occur in order for it to function, to move within the cell, or to fold properly. Methylation, acetylation, phosphorylation, glycosylation, posttranslational cleavage, and the addition of lipid groups are examples of posttranslational modifications. End regions of chromosomes are made up of telomeres, hundreds of repeats of the nucleotide sequence TTAGGG. Some of these telomere sequences are lost each time a cell divides, until they are lost and the cell can no longer divide. This process is called senescence. A polymerase called telomerase is able to replace the DNA sequences at the end regions, allowing for continuing cell division—a significant feature in some cancers.1–6The polypeptide chain formed by the specific amino acid sequence causes the newly formed protein to fold into a tertiary arrangement giving it a 3-dimensional structure. Often, the newly formed protein is inert until made functional by a posttranslational modification such as phosphorylation or proteolytic cleavage. Phosphorylation, the addition to the protein of a phosphate group catalyzed by enzymes called kinases, may cause, for example, translocation of the protein from the cytosol into the nucleus. Dephosphorylation is the removal of a phosphate group catalyzed by enzymes called phosphatases. Phosphorylation and dephosphorylation of proteins are often important in the activation and deactivation of cell cycle proteins, signaling pathway proteins, and transcription factor proteins.1–6Protein degradation is necessary to remove damaged proteins and limit signaling proteins such as those involved in cell survival and cell death. This degradation often needs to proceed quickly. Reversible cross-linkage to a polypeptide, termed ubiquitin, leads to the rapid degradation of proteins and is called ubiquinylation or polyubiquinylation.7The control of gene expression is for the most part controlled by regulation of transcription initiation. Proteins called transcription factors, also termed transactivators or trans-acting factors, bind to DNA and regulate RNA polymerase activity, affecting gene expression either by inducing or activating the gene or by inhibiting the gene by reducing transcription levels.8–13 Transcription factors are necessary for RNA polymerase to initiate transcription, and transcription factors called transcriptional activators stimulate transcription of an RNA molecule from its DNA template.1415A variety of techniques exist for molecular pathology diagnosis, including nucleic acid extraction, Southern blotting, restriction fragment length polymorphism, sequencing, liquid bead microarrays, mass spectrometry, and comparative genomic hybridization, among others. Nucleic acid extraction historically has used organic techniques using chloroform and phenol; however, automated nucleic acid extraction exists today and is frequently used to purify nucleic acids for their use with other molecular methods. For practical laboratory-based molecular diagnosis of lung disease, polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) are 2 of the most important techniques commonly used.In situ hybridization uses DNA or RNA probes to evaluate intact cells for genetic changes. Probes visualized with a chromogen that produces a colored chemical at the reaction site is called chromogenic in situ hybridization and probes using fluorescent labels are called FISH. Evaluation of genetic alterations within intact cells allows for the detection of genetic alterations occurring in a specific group of cells or within a small number of examined cells and is a major benefit of the use of in situ hybridization in anatomic pathology. It is commonly used with cytologic and surgical specimens to detect tumor cells and certain microorganisms, and with surgical specimens of tumors for its prognostic utility and to determine treatment response.16–22 Chromogenic in situ hybridization uses a probe that can be seen as a chromogenic reaction under light microscopy, whereas FISH is available as probe sets and multiprobe FISH cocktails. Peripheral blood, urine, sputum, endoscopic brushings and washings, and paraffin-embedded, formalin-fixed tissue are all suitable for FISH. However, fixation of tissue with formalin for longer than 48 hours may yield poorer FISH results.23DNA and RNA probes hybridize to a specific target sequence that is of interest, for example, genes implicated in a specific type of cancer or an inherited disease, or to a certain microorganism.16–22 Probes are made using DNA fragments cloned from yeast or bacterial artificial chromosomes and, with FISH, are directly or indirectly fluorophore labeled, most often using Texas Red, fluorescing red, and fluorescein isothiocyanate, fluorescing green.24 Directly labeled probes have a fluorophore-labeled nucleotide inserted into the probe, so binding of the probe to its target in 1 hybridization step is all that is required to visualize the probe. Indirectly labeled probes have a reporter molecule such as biotin or digoxigenin attached covalently, requiring the additional step of the application of a fluorophore-labeled avidin or fluorophore-labeled antidigoxigenin. The additional step required with indirectly labeled probes is a disadvantage; however, indirectly labeled probes generally allow for stronger signals because of greater signal amplification.24 There are 4 general types of probes: chromosome enumeration probes, locus-specific indicator probes, telomeric probes, and chromosome paints. Chromosome enumeration probes hybridize to repetitive DNA sequences located near chromosome centromeres, and because the loss of a centromere is generally indicative of the loss of an entire chromosome, they are used to enumerate the number of copies of a certain chromosome within a cell.2526 Locus-specific probes are probes to unique sequences and are most frequently used to determine whether specific genes are amplified, translocated, or deleted. Telomeric probes hybridize to unique DNA sequences located very close to telomeres. The probes do not hybridize to telomeric sequences. Chromosomal paints are a mix of probes that probe to the entire length of 1 or more chromosomes.A FISH specimen must undergo prehybridization to allow a probe to efficiently hybridize to cellular DNA targeted by the probe while protecting the cell from morphologic disruption. Following prehybridization, the probe and cellular DNA are denatured so that the probe can hybridize to the cellular DNA it is targeting. Hybridization usually takes between 4 and 12 hours. A type of DNA called Cot DNA is added during hybridization to hybridize highly repetitive DNA sequences that are located within the genome so that the probe DNA does not nonspecifically bind these repetitive sequences and yield a multitude of nonspecific signals rather than the appropriately specific signal.24252728 The nonbound probe is then removed by washing, a nuclear counterstain that weakly fluoresces is added so that the nucleus can be identified, and an antifade is added to retard fluorophore photobleaching. The signal produced by the FISH fluorophore is then examined with fluorescence microscopy.Since its introduction in 1985,29 PCR has been refined to be an efficient and sensitive method of studying the molecular pathology of primary and metastatic neoplasms, inflammatory mechanisms, and infectious diseases.30–37 Today, automated instruments designed for the laboratory tabletop are available. Polymerase chain reaction amplifies DNA via a repeated 3-step process of denaturation, annealing, and extension. Double-stranded DNA that is the target is denatured at high temperature to yield 2 intact single strands of complementary DNA. Then at a lower temperature, specially designed single-stranded DNA primers anneal or bind to a specific targeted area of the single-stranded DNA. Because there are very large numbers of DNA primers relative to the full-length complementary DNA strand, the target DNA anneals with the primer DNA much more frequently than with the complementary DNA when cooling occurs. In the third step, extension, Taq polymerase identifies the now partially double-stranded DNA and extends the primers by polymerization, to yield, at the end of the first cycle, 2 double-stranded copies of a portion of the target DNA generated from 1 copy. Because the DNA primers only recognize the DNA for which they have been specifically designed, only that specific segment of DNA, making up a small part of the entire DNA present in the original DNA, is preferentially amplified. Subsequent cycles produce numerous shorter double-stranded DNA PCR products, so that more than a billion copies of the original double-stranded DNA are produced after 30 cycles, and more than a trillion are produced after 40 cycles. Following amplification, post-PCR analysis of the markedly increased amount of targeted DNA sequence product can be performed. The target sequence can be shown to be present in a specimen by the use of amplicons run on polyacrylamide or agarose electrophoresis, or via Southern blotting with probe hybridization, comparing the lengths of the targeted DNA sequence with DNA "ladder" markers. DNA sequencing can be performed on the amplicons, or studies to identify mutations may also be performed.3839 Because PCR enormously amplifies DNA, great caution must be used in performing PCR to avoid cross-contamination of a specimen with even very small amounts of DNA.Real-time PCR is becoming a more and more popular method of molecular pathology research and diagnosis that eliminates the need for post-PCR analysis and allows for relatively quick detection of DNA targets, including specific mutations.40–44The best way to examine specific genes present in a certain cell type, such as in tumor cells, is to examine those cells' mRNA. As RNA is not stable enough to work with easily in a laboratory, reverse transcription can be used to convert mRNA into its complementary DNA. With reverse transcription, mRNA is the template used for the production of a strand of DNA, opposite or reverse of typical cellular transcription. The complementary DNA can be used as the template for PCR in a process called reverse transcriptase–PCR (RT-PCR). Reverse transcriptase–PCR can be used to examine genes that are expressed, overexpressed, underexpressed, or not expressed in a specific cell type by the isolation of specific mRNA.44–47 Altered gene expression is a characteristic of malignant transformation, and those alterations allow for the identification of the presence of cancer cells via the detection of mRNA transcripts specific to those tumor cells. Tumor markers have been identified that are specific to solid organ cancers, and RT-PCR is highly sensitive in detecting differentially expressed tumor-related mRNAs. Some studies have indicated that RT-PCR can detect as few as 1 cancer cell in a million normal cells.4448 Real-time quantitative RT-PCR has become popular for detecting and quantifying RNA targets in a variety of cancers. It requires no post-PCR analysis and is efficient and automated. Several studies have used real-time quantitative RT-PCR to evaluate lymph nodes for micrometastases, including for non–small cell lung carcinoma (NSCLC), and to examine peripheral blood for potential dissemination of lung cancer cells during lobectomy.49–52Normal human DNA contains 2 alleles for every genetic locus, the majority of which are identical, or homozygous, and the loss of 1 allele results in no pathologic change. Some genetic loci have 2 differing copies of alleles and are heterozygous. The majority of these heterozygous alleles allow for normal variance and do not result in pathologic changes; however, some of these heterozygous loci have the potential to cause pathologic genetic variations, with resultant disease. If there is a loss of the normal, or "wild-type," allele at a locus, with resultant "loss of heterozygosity," the remaining aberrant allele can cause cellular damage. At homozygous loci, the loss of an allele can occur and be followed by gene silencing or point mutation, causing loss of tumor suppressor genes.5354 Detection of loss of heterozygosity using older methods such as Southern blot analysis and restriction fragment length polymorphism analysis are low-throughput, tedious, and inefficient; however, newer, high-throughput single nucleotide polymorphism arrays have allowed for more efficient examination of loss of heterozygosity.55–57Cancers, including lung cancers, commonly exhibit loss of heterozygosity, causing the inactivation or silencing of genes critical for growth regulation and homeostasis. Cigarette smoking has been associated with loss of heterogeneity of sites on chromosome 3, and the association is greater in patients who began smoking at a young age.58–61 More than 90% of small cell carcinomas and more than 70% of NSCLCs contain loss of heterozygosity.576263 Among NSCLCs, squamous cell carcinomas exhibit loss of heterozygosity in more than 90% of cases, compared with adenocarcinomas, showing loss of heterozygosity in approximately 70% of cases. In NSCLC, loss of heterozygosity generally involves genetic foci on chromosomes 1p, 3p, 8p, 9p, 13q, 17p, 19p, Xp, and Xq. In small cell carcinomas, loss of heterozygosity generally involves chromosomes 3p, 4q, 5q, 4q, 10q, 13q, 15q, and 17p.5762–66 Losses found in both small cell carcinomas and NSCLCs, involving chromosomes 3p, 13q, and 17p, are probably related to inactivation of critical tumor suppressor genes including retinoblastoma, p53, and fragile histidine triad (FHIT).576263 Loss of heterozygosity in premalignant conditions and malignant diseases of the lung represents both early- and late-stage changes in the progression of disease; however, the continuum of losses makes it hard to evaluate the specific contribution of each loss. Loss of heterozygosity has also been identified in some benign lung diseases, including asthma and chronic obstructive pulmonary disease, probably reflecting the genetic predisposition identified in these diseases.67–70 Loss of heterozygosity has also been identified in cases of usual interstitial pneumonia (idiopathic pulmonary fibrosis) and suggests premalignant potential in those cases.71Extracellular messenger molecules such as hormones, inflammatory cytokines, and growth factors, called ligands, bind to specific cell surface receptors and activate messengers within the cytosol leading eventually to activation of nuclear transcription factors that, due to the extracellular message, direct the transcription of a specific gene product, such as the transcription of a protein involved in cell growth. This cascade of events is termed signal transduction, and the series of steps within the cascade is termed signal transduction pathway or signaling pathway. Growth factor receptors are a common cell surface receptor, on which polypeptide growth factors such as epidermal growth factor are ligands attaching to those receptor protein-tyrosine kinases, activating the receptor and causing it to bind with intracellular proteins, which in turn continue the signaling pathway. Epidermal growth factor receptor is a member of the type I growth factor receptor tyrosine kinase family. Epidermal growth factor receptor has other ligands that bind to it other than epidermal growth factor, including transforming growth factor α, and these ligands, receptors, and signaling pathways play a central role in many lung cancers as well as some nonneoplastic pulmonary diseases.72–77The extracellular ligands' "messages" are transmitted via a signaling pathway. Cell differentiation and proliferation, cell survival, and cell death and apoptosis are regulated by signaling pathways, the majority of which "cross-talk" with other signaling pathways in a complex manner. Several important signaling pathways have been well studied. For example, the Wnt/B/catenin pathway, termed the canonical Wnt signaling pathway, involves Wnt binding to Frizzled cell surface receptors, which in turn activate Disheveled, causing the inhibition of protein kinase glycogen synthase kinase 3, which in turn releases dephosphorylated β-catenin from the adenomatous polyposis coli–axin complex. β-Catenin associates with T-cell factor/lymphoid enhancer–binding factor transcription factors causing the induction of Myc.78–84 Other important signaling pathways include the JAK/STAT pathway, involving signal transducers and activators of transcription (STAT) proteins and Janus kinase (JAK) nonreceptor protein tyrosine kinases; the Ras/Raf-1/MAPK pathway, a significant pathway in carcinogenesis, including epithelial cell proliferation; the nuclear factor-κB transcription factor and nuclear factor-κB signaling pathways that regulate immune system proteins, cell survival and proliferation proteins, and apoptosis proteins; and the PI3K/Akt/ mTOR pathway important in regulating cell survival; among many others.85–93Errors in replication, extracellular influences such as UV light, radiation, and chemicals, and endogenous influences such as oxygen radicals routinely cause DNA damage, generally depurination, and with the of a chemical group to DNA, the of which is termed an Several DNA pathways exist to the damaged DNA and replace it with newly DNA based on its complementary DNA DNA pathways are important in an to lung cancer and to lung cancer The base pathway small foci of DNA including or single or fragments and The nucleotide pathway DNA involving both The be because no for the DNA segment is available. can cause DNA such as chemical and The DNA pathway, also termed the break pathway, involves a cascade of events and to double-stranded The direct pathway DNA by in cell cycle is a series of very regulated events cell proliferation, including into DNA replication, replication, into cell cell and cell The cell cycle is into at for DNA synthesis or of and with nuclear and cellular which control of DNA and cell in to and with proteins called that regulate the progression of the series of steps in the cell cycle by activating and proteins by phosphorylation, including proteins that as on cell cycle progression and cell The cell cycle is controlled by many pathways and and and it may be appropriately or in inflammatory Cell cycle regulation loss is a very important step in cell proliferation during cycle damaged DNA to be on to cells by the cell cycle at specific It allows damaged DNA to be the is to cells into apoptosis cell The primary in the cell cycle is the restriction point in to the cell cycle occurs. Other include an and a A complex of proteins, the complex and the detect DNA at these DNA is the DNA is and the cell cycle factor signaling the cell cycle and the the however, once the cell the cell restriction it no longer requires growth factor and the cell is to the cell The gene product, progression past the restriction point of the cell cycle and the expression of genes involved in DNA of the cell cycle also on activation of of the of p53, the gene product, is to the DNA the of the cell cycle at in to DNA or to the induction of apoptosis when is As has been to as the of the and have critical in the of the cell cycle, and of and are the most common associated with the cell cycle of however, due to the large number of and pathways, many can produce direct or loss. The gene for 2 protein products, a kinase and of either of these can produce of the or of and as well as other genes and their or of and p53, can produce loss of cell cycle control the direct loss of and and prognostic techniques using molecular are used in anatomic pathology genes for proliferation, and the used for of molecular and factors involved in genetic will the current and molecular testing and their to the diagnosis and of lung

Differentiation Hotspots on a Cell Cycle Related Continuum.